Product Description
MB-107 is a safety modified lentiviral (LV) vector as X-linked severe combined immunodeficiency (XSCID) gene therapy. (Sourced from: https://www.mustangbio.com/pipeline/)
Mechanisms of Action: Gene Therapy, IL2RG
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: Orphan Drug - Severe Combined Immunodeficiency *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fortress Biotech
Company Location: Eastern America
Company CEO: Alexandra MacLean
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: X-Linked Combined Immunodeficiency Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/23/2025 |
News Article |
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer |
|
08/13/2025 |
News Article |
Moleculin Reports Second Quarter 2025 Financial Results and Highlights |
|
06/11/2025 |
News Article |
Moleculin Participates in Virtual Investor "What This Means" Segment |
|
06/05/2025 |
News Article |
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) |